NEW YORK (GenomeWeb News) – Shares in Affymetrix plummeted more than 13 percent in afternoon trading today on Nasdaq after an analyst from Barclay's Capital downgraded the firm from "equal weight" to "underweight."

Shares of Affymetrix were trading at $5.58 this afternoon, a decrease of $0.86 from yesterday's closing price of $6.44.

The Barclay's analyst downgraded Affymetrix's stock based on the recent introduction of competing technologies that are rendering Affymetrix's products "obsolete."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.